01 March 2024
Physiomics plc
("Physiomics" or "the Company")
Notice of Results and Investor
Presentation
Physiomics plc (AIM: PYC), a leading
mathematical modelling and data science company supporting the
development of new therapeutics and personalised medicine
solutions, is pleased to announce that it will be posting its
interim results on Thursday 7 March 2024.
The Company will provide a live
presentation update in-line with these results via
Investor Meet Company on 18 March 2024 at 12:00 pm GMT. During this
presentation, Peter Sargent (CEO) and Jim Millen (Chairman) would
be happy to take questions relating to the Company's interim
results and more broadly about the business.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 17
March 2024, 09:00 am GMT, or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet PHYSIOMICS PLC
via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
Investors who already follow
PHYSIOMICS PLC on the Investor Meet Company platform will
automatically be invited.
Enquiries:
Physiomics
plc
Dr Jim Millen, Non-Executive Chairman, +44
(0)1865 784 980
Dr Peter Sargent, Chief Executive Officer, +44
(0)1865 784 980
Hybridan LLP
(Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson
Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to
Editor
About Physiomics
Physiomics plc (AIM: PYC) is an
oncology consultancy using mathematical models to support the
development of cancer treatment regimens and personalised medicine
solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to
improve the success rate of drug discovery and development projects
while reducing time and cost. The predictive capability of
Physiomics' technologies have been confirmed by over 100 projects,
involving over 50 targets and 75 drugs, and has worked with clients
such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.